Alexion Secures Funding OK In England For GI Bleeding But Wants More
Company Is Seeking Coverage For Treatment Of Intracranial Hemorrhage
Alexion is collecting more evidence to convince NICE that its anticoagulant reversal agent is also cost-effective for intracranial hemorrhage.
You may also be interested in...
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
Although the health technology assessment institute for England has provisionally recommended against the use of Europe’s first and only approved drug for reversing the effects of factor Xa anticoagulants, Portola believes it may now have the evidence needed to reverse this decision.
Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.